Food for Thought ... 3S – Systematic, Systemic, and Systems Biology and Toxicology

Altex

Volumn 35, Issue 2, 2018, Pages 139-162

  Smirnova, Lena ^a   Kleinstreuer, Nicole ^b   Corvi, Raffaella ^c   Levchenko, Andre ^d   Fitzpatrick, Suzanne C ^e   Hartung, Thomas ^a,f  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c JOINT RESEARCH CENTRE   (Italy)

^d Yale University   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

carcinogenicity; DART; evidence based toxicology; repeated dose toxicity; systems biology

Indexed keywords

ANIMAL; ANIMAL TESTING ALTERNATIVE; BIOLOGICAL MODEL; COMPUTER SIMULATION; HUMAN; SYSTEMS BIOLOGY; TOXICOLOGY; TRENDS;

ANIMAL TESTING ALTERNATIVES; ANIMALS; COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; SYSTEMS BIOLOGY; TOXICOLOGY;

EID: 85055346186     PISSN: 1868596X     EISSN: 18688551     Source Type: Journal    
DOI: 10.14573/altex.1804051     Document Type: Article

References (220)

1. Abaci, H. E. and Shuler, M. L. (2015). Human-on-a-chip design strategies and principles for physiologically based pharmacokinetics/pharmacodynamics modeling. Integr Biol 7, 383-391. doi:10.1039/C4IB00292J
2. Adler, S., Basketter, D., Creton, S. et al. (2011). Alternative (non-animal) methods for cosmetics testing: Current status and future prospects. Arch Toxicol 85, 367-485. doi:10.1007/s00204-011-0693-2
3. Ågerstrand, M. and Beronius, A. (2016). Weight of evidence evaluation and systematic review in EU chemical risk assessment: Foundation is laid but guidance is needed. Env Int 92-93, 590-596. doi:10.1016/j.envint.2015.10.008
4. Aiassa, E., Higgins, J. P. T., Frampton, G. K. et al. (2015). Applicability and feasibility of systematic review for performing evidence-based risk assessment in food and feed safety. Crit Rev Food Sci Nutr 55, 1026-1034. doi:10.1080/10408398.20 13.769933
5. Alden, C. L., Lynn, A., Bourdeau, A. et al. (2011). A critical review of the effectiveness of rodent pharmaceutical carcinogenesis testing in predicting human risk. Vet Pathol 48, 772-784. doi:10.1177/0300985811400445
6. 4 report. ALTEX 31, 441-477. doi:10.14573/ altex1406111
7. Anand, P., Kunnumakara, B. A., Sundaram, C. et al. (2008). Cancer is a preventable disease that requires major lifestyle changes. Pharm Res 25, 2097-2116. doi:10.1007/s11095-008-9661-9
8. Andersen, M. E., Betts, K., Dragan, Y. et al. (2014). Developing microphysiological systems for use as regulatory tools – Challenges and opportunities. ALTEX 31, 364-367. doi:10.14573/ altex.1405151
9. Anisimov, V. N., Ukraintseva, S. V. and Yashin, A. I. (2005). Cancer in rodents: Does it tell us about cancer in humans? Nat Rev Cancer 5, 807-819. doi:10.1038/nrc1715
10. Ashby, J. and Tennant, R. W. (1991). Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutat Res 257, 229-306. doi:10.1016/0165-1110(91)90003-E
11. Bal-Price, A., Hogberg, H. T., Crofton, K. M. et al. (2018). Recommendation on test readiness criteria for new approach methods in toxicology: Exemplified for developmental neurotoxicity. ALTEX, Epub ahead of print. doi:10.14573/altex.1712081
12. Bailey, J., Knight, A. and Balcombe, J. (2005). The future of teratology research is in vitro. Biogenic Amines 19, 97-145. doi:10.1163/1569391053722755
13. Baker, M. (2016). Is there a reproducibility crisis? Nature 533, 452-454. doi:10.1038/533452a
14. Basketter, D. A., Clewell, H., Kimber, I. et al. (2012). A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing. ALTEX 29, 3-91. doi:10.14573/ altex.2012.1.003
15. Batke, M., Aldenberg, T., Escher, S. and Mangelsdorf, I. (2013). Relevance of non-guideline studies for risk assessment: The coverage model based on most frequent targets in repeated dose toxicity studies. Toxicol Lett 218, 293-298. doi:10.1016/j. toxlet.2012.09.002
16. Bernauer, U., Heinemeyer, G., Heinrich-Hirsch, B. et al. (2008). Exposure-triggered reproductive toxicity testing under the REACH legislation: A proposal to define significant/ relevant exposure. Toxicol Lett 176, 68-76. doi:10.1016/j. toxlet.2007.10.008
17. Bernstein, L., Gold, L. S., Ames, B. N. et al. (1985). Some tautologous aspects of the comparison of carcinogenic potency in rats and mice. Fundam Appl Toxicol 5, 79-86. doi:10.1016/0272-0590(85)90051-X
18. Birnbaum, L. S. and Fenton, S. (2003). Cancer and developmental exposure to endocrine disruptors. Environ Health Perspect 111, 389-394. doi:10.1289/ehp.5686
19. Bokkers, B. G. H. and Slob, W. (2007). Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach. Crit Rev Toxicol 37, 355-373. doi:10.1080/10408440701249224
20. Bottini, A. A., Alepee, N., De Silva, O. et al. (2008). Optimization of the post-validation process. The report and recommendations of ECVAM workshop 67. Altern Lab Anim 36, 353-366.
21. Bouhifd, M., Andersen, M. E., Baghdikian, C. et al. (2015). The human toxome project. ALTEX 32, 112-124. doi:10.14573/ altex.1502091
22. Bremer, S. and Hartung, T. (2004). The use of embryonic stem cells for regulatory developmental toxicity testing in vitro – The current status of test development. Curr Pharm Des 10, 2733-2747. doi:10.2174/1381612043383700
23. Bremer, S., Pellizzer, C., Hoffmann, S. et al. (2007). The development of new concepts for assessing reproductive toxicity applicable to large scale toxicological programs. Curr Pharm Des 13, 3047-3058. doi:10.2174/138161207782110462
24. Brown, N. A. and Fabro, S. (1983). The value of animal teratogenicity testing for predicting human risk. Clin Obstet Gynecol 26, 467-477. doi:10.1097/00003081-198306000-00028
25. Busquet, F. and Hartung, T. (2017). The need for strategic development of safety sciences. ALTEX 34, 3-21. doi:10.14573/ altex.1701031
26. Carney, E. W., Ellis, A. L., Tyl, R. W. et al. (2011). Critical evaluation of current developmental toxicity testing strategies: A case of babies and their bathwater. Birth Defects Res B: Develop Reprod Toxicol 92, 395-403. doi:10.1002/bdrb.20318
27. Chen, M., Bisgin, H., Tong, L. et al. (2014). Toward predictive models for drug-induced liver injury in humans: Are we there yet? Biomark Med 8, 201-213. doi:10.2217/bmm.13.146
28. Chen, S.-H., Forrester, W. and Lahav, G. (2016). Schedule-dependent interaction between anticancer treatments. Science 351, 1204-1208. doi:10.1126/science.aac5610
29. Chiu, W. A., Guyton, K. Z., Martin, M. T. et al. (2018). Use of high-throughput in vitro toxicity screening data in cancer hazard evaluations by IARC Monograph Working Groups. ALTEX 35, 51-64. doi:10.14573/altex.1703231
30. Christianson, A., Howson, C. P. and Modell, B. (2006). March of Dimes Global Report of Birth Defects: The hidden toll of dying and disabled children. New York, USA: March of Dimes Birth Defects Foundation. https://bit.ly/2GFyjXi
31. Coecke, S., Balls, M., Bowe, G. et al. (2005). Guidance on good cell culture practice. Altern Lab Anim 33, 261-287.
32. Colditz, G. A. and Wei, E. K. (2012). Preventability of cancer: The relative contributions of biologic and social and physical environmental determinants of cancer mortality. Annual Rev Publ Health 33, 137-156. doi:10.1146/annurev-publhealth-031811-124627
33. Collins, T. F. (2006). History and evolution of reproductive and developmental toxicology guidelines. Curr Pharm Des 12, 1449-1465. doi:10.2174/138161206776389813
34. Combes, R., Balls, M., Curren, R. et al. (1999). Cell transformation assay as predictors of human carcinogenicity. Altern Lab Anim 27, 745-767.
35. Corvi, R., Albertini, S., Hartung, T. et al. (2008). ECVAM retrospective validation of in vitro micronucleus test (MNT). Mutagenesis 23, 271-283. doi:10.1093/mutage/gen010
36. Corvi, R., Aardema, M. J., Gribaldo, L. et al. (2012). ECVAM prevalidation study on in vitro cell transformation assays: General outline and conclusions of the study. Mut Res 744, 12-19. doi:10.1016/j.mrgentox.2011.11.009
37. Corvi, R., Vilardell, M., Aubrecht, J. and Piersma, A. (2016). Validation of transcriptomics-based in vitro methods. In C. Eskes and M. Whelan (eds.), Validation of Alternative Methods for Toxicity Testing, Advances in Experimental Medicine and Biology. Vol. 856, 243-257. Switzerland: Springer. doi:10.1007/978-3-319-33826-2_10
38. Corvi, R. and Madia, F. (2017). In vitro genotoxicity testing: Can the performance be enhanced? Food Chem Toxicol 106, 600-608. doi:10.1016/j.fct.2016.08.024
39. Corvi, R., Madia, F., Guyton, K. Z. et al. (2017). Moving forward in carcinogenicity assessment: Report of an EURL ECVAMESTIV workshop. Toxicol In Vitro 45, 278-286. doi:10.1016/j. tiv.2017.09.010
40. Daneshian, M., Busquet, F., Hartung, T. and Leist, M. (2015). Animal use for science in Europe. ALTEX 32, 261-274. doi:10.14573/altex.1509081
41. Daneshian, M., Kamp, H., Hengstler, J. et al. (2016). Highlight report: Launch of a large integrated European in vitro toxicology project: EU-ToxRisk. Arch Toxicol 90, 1021-1024. doi:10.1007/s00204-016-1698-7
42. Daston, G. P. and Seed, J. (2007). Skeletal malformations and variations in developmental toxicity studies: Interpretation issues for human risk assessment. Birth Defects Res B Dev Reprod Toxicol 80, 421-424. doi:10.1002/bdrb.20135
43. Doe, J. E., Boobis, A. R., Blacker, A. et al. (2006). A tiered approach to systemic toxicity testing for agricultural chemical safety assessment. Crit Rev Toxicol 36, 37-68. doi:10.1080/10408440500534370
44. Doktorova, T. Y., Yildirimman, R., Celeen, L. et al. (2014). Testing chemical carcinogenicity by using a transcriptomics HepaRG-based model? EXCLI J 13, 623-637.
45. Ellis-Hutchings, R., Settivari, R., McCoy, A. et al. (2017). Embryonic vascular disruption adverse outcomes: Linking HTS signatures with functional consequences. Reprod Toxicol 70, 82-96. doi:10.1016/j.reprotox.2017.04.003
46. Ennever, F. K., Noonan, T. J. and Rosenkranz, H. S. (1987). The predictivity of animal bioassays and short-term genotoxicity tests for carcinogenicity and non-carcinogenicity to humans. Mutagenesis 2, 73-78. doi:10.1093/mutage/2.2.73
47. Ennever, F. K. and Lave, L. B. (2003). Implications of the lack of accuracy of the lifetime rodent bioassay for predicting human carcinogenicity. Regul Toxicol Pharmacol 38, 52-57. doi:10.1016/S0273-2300(03)00068-0
48. Eskes, C., Boström, A.-C., Bowe, G. et al. (2017). Good cell culture practices & in vitro toxicology. Toxicol In Vitro 45, 272-277. doi:10.1016/j.tiv.2017.04.022
49. EURL ECVAM (2012). EURL ECVAM Recommendation on three cell transformation assays using Syrian hamster embryo cells (SHE) and the BALB/c 3T3 mouse fibroblast cell line for in vitro carcinogenicity testing. https://bit.ly/2qbJ50J
50. EURL ECVAM (2013a). EURL ECVAM strategy to avoid and reduce animal use in genotoxicity testing. JRC Report EUR 26375. https://bit.ly/19V6dzF
51. EURL ECVAM (2013b). EURL ECVAM Recommendation on cell transformation assay based on the Bhas 42 cell line. https://bit.ly/2qbJ50J
52. Ewart, L., Fabre, K., Chakilam, A. et al. (2017). Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective. Exp Biol Med 242, 1579-1585. doi:10.1177/1535370217715441
53. Ferrario, D., Brustio, R. and Hartung, T. (2014). Glossary of reference terms for alternative test methods and their validation. ALTEX 31, 319-335. doi:10.14573/altex.140331
54. Freedman, D. A. and Zeisel, H. (1988). From mouse to man: The quantitative assessment of cancer risks. Statist Sci 3, 3-56. doi:10.1214/ss/1177012993
55. Freedman, L. P., Cockburn, I. M. and Simcoe, T. S. (2015). The economics of reproducibility in preclinical research. PLoS Biol 13, e1002165. doi:10.1371/journal.pbio.1002165
56. Gaylor, D. W. (2005). Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens? Regul Toxicol Pharmacol 41, 128-133. doi:10.1016/j. yrtph.2004.11.001
57. GBD 2013 Risk Factors Collaborators (2013). Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the global burden of disease study 2013. Lancet 386, 2287-2323. doi:10.1016/S0140-6736(15)00128-2
58. Genschow, E., Spielmann, H., Scholz, G. et al. (2004). Validation of the embryonic stem cell test in the international ECVAM validation study on three in vitro embryotoxicity tests. Altern Lab Anim 32, 209-244.
59. Gold, L. S., Slone, T. H., Manley, N. B. et al. (1991). Target organs in chronic bioassays of 533 chemical carcinogens. Environ Health Perspect 93, 233-246. doi:10.1289/ehp.9193233
60. Gold, L. S., Slone, T. H. and Ames, B. N. (1998). What do animal cancer tests tell us about human cancer risk? Overview of analyses of the carcinogenic potency database. Drug Metab Rev 30, 359-404. doi:10.3109/03602539808996318
61. Gordon, S., Daneshian, M., Bouwstra, J. et al. (2015). Non-animal models of epithelial barriers (skin, intestine and lung) in research, industrial applications and regulatory toxicology. ALTEX 32, 327-378. doi:10.14573/altex.1510051
62. Gottmann, E., Kramer, S., Pfahringer, B. and Helma, C. (2001). Data quality in predictive toxicology: Reproducibility of rodent carcinogenicity experiments. Environ Health Perspect 109, 509-514. doi:/10.1289/ehp.01109509
63. Gray, G. M., Li, P., Shlyakhter, I. and Wilson, R. (1995). An empirical examination of factors influencing prediction of carcinogenic hazard across species. Regul Toxicol Pharmacol 22, 283-291. doi:10.1006/rtph.1995.0011
64. Griesinger, C., Hoffmann, S., Kinsner-Ovaskainen, A. et al. (2008). Proceedings of the First International Forum Towards Evidence-Based Toxicology. Conference Centre Spazio Villa Erba, Como, Italy. 15-18 October 2007. Human Exp Toxicol 28, Spec Issue: Evidence-Based Toxicology (EBT) 2009, 71-163.
65. Hardy, B., Apic, G., Carthew, P. et al. (2012a). Food for thought ... A toxicology ontology roadmap. ALTEX 29, 129-137. doi:10.14573/altex.2012.2.129
66. Hardy, B., Apic, G., Carthew, P. et al. (2012b). Toxicology ontology perspectives. ALTEX 29, 139-156. doi:10.14573/ altex.2012.2.139
67. Hareng, L., Pellizzer, C., Bremer, S. et al. (2005). The integrated project ReProTect: A novel approach in reproductive toxicity hazard assessment. Reprod Toxicol 20, 441-452. doi:10.1016/j. reprotox.2005.04.003
68. Hartung, T., Bremer, S., Casati, S. et al. (2004). A modular approach to the ECVAM principles on test validity. Altern Lab Anim 32, 467-472.
69. Hartung, T. (2007). Food for thought … on validation. ALTEX 24, 67-72. doi:10.14573/altex.2007.2.67
70. Hartung, T. (2008a). Food for thought … on animal tests. ALTEX 25, 3-9. doi:10.14573/altex.2008.1.3
71. Hartung, T. (2008b). Toward a new toxicology – Evolution or revolution? Altern Lab Anim 36, 635-639.
72. Hartung, T. (2008c). Food for thought … on alternative methods for cosmetics safety testing. ALTEX 25, 147-162. doi:10.14573/ altex.2008.3.147
73. Hartung, T. (2009a). Food for thought … on evidence-based toxicology. ALTEX 26, 75-82. doi:10.14573/altex.2009.2.75
74. Hartung, T. (2009b). Toxicology for the twenty-first century. Nature 460, 208-212. doi:10.1038/460208a
75. Hartung, T. and Rovida, C. (2009). Chemical regulators have overreached. Nature 460, 1080-1081. doi:10.1038/4601080a
76. Hartung, T. and Hoffmann, S. (2009). Food for thought … on in silico methods in toxicology. ALTEX 26, 155-166. doi:10.14573/ altex.2009.3.155
77. st century? ALTEX 27, 241-251. doi:10.14573/altex.2010.4.253
78. Hartung, T. (2010b). Food for thought… on alternative methods for chemical safety testing. ALTEX 27, 3-14. doi:10.14573/ altex.2010.1.3
79. Hartung, T., Blaauboer, G. J., Bosgra, S. et al. (2011). An expert consortium review of the EC-commissioned report “Alternative (non-animal) methods for cosmetics testing: current status and future prospects – 2010”. ALTEX 28, 183-209. doi:10.14573/ altex.2011.3.183
80. Hartung, T., van Vliet, E., Jaworska, J. et al. (2012). Systems toxicology. ALTEX 29, 119-128. doi:10.14573/altex.2012.2.119
81. Hartung, T. (2013). Look back in anger – What clinical studies tell us about preclinical work. ALTEX 30, 275-291. doi:10.14573/ altex.2013.3.275
82. Hartung, T., Luechtefeld, T., Maertens, A. and Kleensang, A. (2013). Integrated testing strategies for safety assessments. ALTEX 30, 3-18. doi:10.14573/altex.2013.1.003
83. Hartung, T. (2014). 3D – A new dimension of in vitro research. Adv Drug Deliv Rev 69-70, vi. Preface Special Issue “Innovative tissue models for in vitro drug development”.
84. Hartung, T. (2016). Making big sense from big data in toxicology by read-across. ALTEX 33, 83-93. doi:10.14573/altex.1603091
85. Hartung, T. (2017a). Food for thought ... the first ten years. ALTEX 34, 187-192. doi:10.14573/altex.1703311
86. Hartung, T. (2017b). Opinion versus evidence for the need to move away from animal testing. ALTEX 34, 193-200. doi:10.14573/ altex.1703291
87. Hartung, T. (2017c). Thresholds of toxicological concern – Setting a threshold for testing where there is little concern. ALTEX 34, 331-351. doi:10.14573/altex.1707011
88. Hartung, T. (2017d). Utility of the adverse outcome pathway concept in drug development. Exp Opin Drug Metabol Toxicol 13, 1-3. doi:10.1080/17425255.2017.1246535
89. Hartung, T., FitzGerald, R., Jennings, P. et al. (2017a). Systems toxicology – Real world applications and opportunities. Chem Res Toxicol 30, 870-882. doi:10.1021/acs.chemrestox.7b00003
90. Hartung, T., Kavlock, R. and Sturla, S. (2017b). Systems toxicology II: A special issue. Chem Res Toxicol 30, 869-869. doi:10.1021/acs.chemrestox.7b00038
91. Hartung, T. (2018). Perspectives on in vitro to in vivo extrapolations. J Appl In Vitro Toxicol, in press. doi:10.1089/ aivt.2016.0026
92. Haseman, J. K., Boorman, G. A. and Huff, J. (1997). Value of historical control data and other issues related to the evaluation of long-term rodent carcinogenicity studies. Toxicol Pathol 25, 524-527. doi:10.1177/019262339702500518
93. Hatzivassiliou, G., Song, K., Yen, I. et al. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435. doi:10.1038/nature08833
94. Hengstler, J. G., van der Burg, B., Steinberg, P. and Oesch, F. (1999). Interspecies differences in cancer susceptibility and toxicity. Drug Metab Rev 31, 917-970. doi:10.1081/DMR-100101946
95. Hengstler, J. G., Marchan, R. and Leist, M. (2012). Highlight report: Towards the replacement of in vivo repeated dose systemic toxicity testing. Arch Toxicol 86, 13-15. doi:10.1007/ s00204-011-0798-7
96. Herwig, R., Gmuender, H., Corvi, R. et al. (2016). Inter-laboratory study of human in vitro toxicogenomics-based tests as alternative methods for evaluating chemical carcinogenicity: A bioinformatics perspective. Arch Toxicol 90, 2215-2229. doi:10.1007/s00204-015-1617-3
97. Hoffmann, S. and Hartung, T. (2006). Towards an evidence-based toxicology. Hum Exp Toxicol 25, 497-513. doi:10.1191/0960327106het648oa
98. Hoffmann, S., Edler, L., Gardner, I. et al. (2008). Points of reference in validation – The report and recommendations of ECVAM Workshop. Altern Lab Anim 36, 343-352.
99. Hoffmann, S., de Vries, R. B. M., Stephens, M. L. et al. (2017). A primer on systematic reviews in toxicology. Arch Toxicol 91, 2551-2575. doi:10.1007/s00204-017-1980-3
100. Hoke, R. A. and Ankley, G. T. (2005). Application of frog embryo teratogenesis assay-Xenopus to ecological risk assessment. Environ Toxicol Chem 24, 2677-2690. doi:10.1897/04-506R.1
101. Hotchkiss, A. K., Rider, C. V., Blystone, C. R. et al. (2008). Fifteen years after “Wingspread” – Environmental endocrine disrupters and human and wildlife health: Where we are today and where we need to go. Toxicol Sci 105, 235-259. doi:10.1093/ toxsci/kfn030
102. Hurtt, M. E., Cappon, G. D. and Browning, A. (2003). Proposal for a tiered approach to developmental toxicity testing for veterinary pharmaceutical products for food-producing animals. Food Chem Toxicol 41, 611-619. doi:10.1016/S0278-6915(02)00326-5
103. Hutson, M. S., Leung, M., Baker, N. C. et al. (2017). Computational model of secondary palate fusion and disruption. Chem Res Toxicol 30, 965-979. doi:10.1021/acs.chemrestox.6b00350
104. ICCVAM (2018). A Strategic Roadmap for Establishing New Approaches to Evaluate the Safety of Chemicals and Medical Products in the United States. January 2018. https://ntp.niehs.nih.gov/go/natl-strategy (accessed 22.03.2018).
105. ICH (2009). S1B Guideline on Carcinogenicity Testing of Pharmaceuticals. EMA Document CPMP/ICH/299/95. https://bit.ly/2H3PTrw
106. ICH Status Report (2016). The ICHS1 Regulatory Testing Paradigm of Carcinogenicity in rats – Status Report. Safety Guidelines, 2 March, 1-5. https://bit.ly/2IzczwZ
107. ILSI HESI ACT (2001). ILSI HESI Alternatives to carcinogenicity testing project. Toxicol Pathol 29, Suppl, 1-351.
108. Jacobs, M. N., Colacci, A., Louekari, K. et al. (2016). International regulatory needs for development of an IATA for non-genotoxic carcinogenic chemical substances. ALTEX 33, 359-392. doi:10.14573/altex.1601201
109. Janer, G., Hakkert, B. C., Slob, W. et al. (2007). A retrospective analysis of the two-generation study: What is the added value of the second generation? Reprod Toxicol 24, 97-102. doi:10.1016/j.reprotox.2007.04.068
110. Jemal, A., Siegel, R., Ward, E. et al. (2009). Cancer statistics, 2009. CA Cancer J Clin 59, 225-249. doi:10.3322/caac.20006
111. Jilka, R. L. (2016). The road to reproducibility in animal research. J Bone Mineral Res 31, 1317-1319. doi:10.1002/jbmr.2881
112. Johnson,F.M.(2001).ResponsetoTennantetal.:Attemptstoreplace the NTProdent bioassay with transgenic alternatives are unlikely to succeed. Environ Mol Mutagen 37, 89-92. doi:10.1002/1098-2280(2001)37:1<89::AID-EM1011>3.0.CO;2-4
113. Joyner, M. J. and Pedersen, B. K. (2011). Ten questions about systems biology. J Physiol 589, 1017-1030. doi:10.1113/ jphysiol.2010.201509
114. Judson, R., Houck, K., Martin, M. et al. (2016). Analysis of the effects of cell stress and cytotoxicity on in vitro assay activity across a diverse chemical and assay space. Toxicol Sci 152, 323-339. doi:10.1093/toxsci/kfw092
115. Kennedy, T. (1997). Managing the drug discovery/development interface. Drug Discov Today 2, 436-444. doi:10.1016/S1359-6446(97)01099-4
116. Kessler, R. (2014). Air of danger. Nature S62, 509. doi:10.1038/509S62a
117. Kholodenko, B. N. (2015). Drug resistance resulting from kinase dimerization is rationalized by thermodynamic factors describing allosteric inhibitor effects. Cell Reports 12, 1939-1949. doi:10.1016/j.celrep.2015.08.014
118. Kiani, N. A., Shang, M.-M. and Tegner, J. (2016). Systems toxicology: Systematic approach to predict toxicity. Curr Pharm Des 22, 6911-6917. doi:10.2174/13816128226661610031156 29
119. Kilic, O., Pamies, D., Lavell, E. et al. (2016). Microphysiological brain model enables analysis of neuronal differentiation and chemotaxis. Lab Chip 16, 4152-4162. doi:10.1039/ C6LC00946H
120. Kim, J. H. and Scialli, A. R. (2011). Thalidomide: The tragedy of birth defects and the effective treatment of disease. Toxicol Sci 122, 1-6. doi:10.1093/toxsci/kfr088
121. Kirkland, D., Aardema, M., Henderson, L. and Müller, L. (2005). Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat Res 584, 1-256. doi:10.1016/j.mrgentox.2005.02.004
122. Kirkland, D., Pfuhler, S., Tweatsm, D. et al. (2007). How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow up animal tests: Report of an ECVAM Workshop. Mutat Res 628, 31-55. doi:10.1016/j.mrgentox.2006.11.008
123. Kirkland, D., Reeve, L., Gatehouse, D. and Vanparys, P. (2011). A core in vitro genotoxicity battery comprising the Ames test plus the in vitro micronucleus test is sufficient to detect rodent carcinogens and in vivo genotoxins. Mutat Res 721, 27-73. doi:10.1016/j.mrgentox.2010.12.015
124. Kleinstreuer, N., Dix, D., Houck, K. et al. (2013a). In vitro perturbations of targets in cancer hallmark processes predict rodent chemical carcinogenesis. Toxicol Sci 131, 40-55. doi:10.1093/ toxsci/kfs285
125. Kleinstreuer, N., Dix, D., Rountree, M. et al. (2013b). A computational model predicting disruption of blood vessel development. PLoS Comput Biol 9, e1002996. doi:10.1371/journal. pcbi.1002996
126. Kleinstreuer, N., Houck, K., Yang, J. et al. (2014). Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms. Nat Biotechnol 32, 583-591. doi:10.1038/nbt.2914
127. Kleinstreuer, N. C., Ceger, P., Watt, E. D. et al. (2016). Development and validation of a computational model for androgen receptor activity. Chem Res Toxicol 30, 946-964. doi:10.1021/ acs.chemrestox.6b00347
128. Kleinstreuer, N., Hoffmann, S., Alepee, N. et al. (2018). Non-animal methods to predict skin sensitization (II): An assessment of defined approaches. Crit Rev Toxicol 23, 1-16. doi:10.1080/10 408444.2018.1429386
129. Knight, A., Bailey, J. and Balcombe, J. (2006a). Animal carcinogenicity studies: 2. Obstacles to extrapolation of data to humans. Altern Lab Anim 34, 29-38.
130. Knight, A., Bailey, J. and Balcombe, J. (2006b). Animal carcinogenicity studies: 1. Poor human predictivity. Altern Lab Anim 34, 19-27.
131. Knudsen, T. B., Kavlock, R. J., Daston, G. P. et al. (2011). Developmental toxicity testing for safety assessment: New approaches and technologies. Birth Defects Res B Dev Reprod Toxicol 92, 413-420. doi:10.1002/bdrb.20315
132. Knudsen, T. B and Kleinstreuer, N. C. (2012). Disruption of embryonic vascular development in predictive toxicology. Birth Defects Res C Embryo Today 93, 312-323. doi:10.1002/bdrc.20223
133. Kola, I. and Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3, 711-715. doi:10.1038/nrd1470
134. Kubinyi, H. (2003). Drug research: Myths, hype and reality. Nat Rev Drug Discov 2, 665-668. doi:10.1038/nrd1156
135. Laufersweiler, M. C., Gadagbui, B., Baskerville-Abraham, I. M. et al. (2012). Correlation of chemical structure with reproductive and developmental toxicity as it relates to the use of the threshold of toxicological concern. Regulat Toxicol Pharmacol 62, 160-182. doi:10.1016/j.yrtph.2011.09.004
136. Lave, L. B., Ennever, F. K., Rosenkranz, H. S. and Omenn, G. S. (1988). Information value of the rodent bioassay. Nature 336, 631-633. doi:10.1038/336631a0
137. LeBoeuf, R. A., Kerckaert, K. A., Aardema, M. J. and Isfort, R. J. (1999). Use of Syrian hamster embryo and BALB/c 3T3 cell transformation for assessing the carcinogenic potential of chemicals. IARC Sci Publ 146, 409-425.
138. Lee, M. J., Ye, A. S., Gardino, A. K. et al. (2012). Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780-794. doi:10.1016/j. cell.2012.03.031
139. Leist, M., Bremer, S., Brundin, P. et al. (2008). The biological and ethical basis of the use of human embryonic stem cells for in vitro test systems or cell therapy. ALTEX 25, 163-190. doi:10.14573/altex.2008.3.163
140. Leist, M., Hasiwa, M., Daneshian, M. and Hartung, T. (2012). Validation and quality control of replacement alternatives – Current status and future challenges. Toxicol Res 1, 8. doi:10.1039/ c2tx20011b
141. Leist, M., Hasiwa, N., Rovida, C. et al. (2014). Consensus report on the future of animal-free systemic toxicity testing. ALTEX 31, 341-356. doi:10.14573/altex.1406091
142. Leist, M., Ghallab, A., Graepel, R. et al. (2017). Adverse outcome pathways: Opportunities, limitations and open questions. Arch Toxicol 91, 3477-3505. doi:10.1007/s00204-017-2045-3
143. Leung, M. C., Phuong, J., Baker, N. C. et al. (2016). Systems toxicology of male reproductive development: Profiling 774 chemicals for molecular targets and adverse outcomes. Environ Health Perspect 124, 1050-1061. doi:10.1289/ehp.1510385
144. Luechtefeld, T., Maertens, A., Russo, D. P. et al. (2016a). Global analysis of publicly available safety data for 9,801 substances registered under REACH from 2008-2014. ALTEX 33, 95-109. doi:10.14573/altex.1510052
145. Luechtefeld, T., Maertens, A., Russo, D. P. et al. (2016b). Analysis of public oral toxicity data from REACH registrations 2008-2014. ALTEX 33, 111-122. doi:10.14573/altex.1510054
146. Luechtefeld, T. and Hartung, T. (2017). Computational approaches to chemical hazard assessment. ALTEX 34, 459-478. doi:10.14573/altex.1710141
147. MacDonald, J., French, J. E., Gerson, R. J. et al. (2004). The utility of genetically modified mouse assays for identifying human carcinogens: A basic understanding and path forward. Toxicol Sci 77, 188-194. doi:10.1093/toxsci/kfh037
148. Madia, F., Worth, A. and Corvi, R. (2016). Analysis of carcinogenicity testing for regulatory purposes in the European Union (92 pp). JRC Report EUR 27765.
149. Mandrioli, D. and Silbergeld, E. K. (2016). Evidence from toxicology: The most essential science for prevention. Environ Health Perspect 124, 6-11. doi:10.1289/ehp.1509880
150. Martin, M. T., Judson, R. S., Reif, D. M. et al. (2009a). Profiling chemicals based on chronic toxicity results from the U.S. EPA ToxRef database. Environ Health Perspect 117, 392-399. doi:10.1289/ehp.0800074
151. Martin, M. T., Mendez, E., Corum, D. G. et al. (2009b). Profiling the reproductive toxicity of chemicals from multigenerationstudies in the toxicity reference database. Toxicol Sci 110, 181-190. doi:10.1093/toxsci/kfp080
152. Marx, J. (2003). Building better mouse models for studying cancer. Science 299, 1972-1975. doi:10.1126/science.299.5615.1972
153. Marx, U., Andersson, T. B., Bahinski, A. et al. (2016). Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing using animals. ALTEX 33, 272-321. doi:10.14573/altex.1603161
154. Marx-Stoelting, P., Adriaens, E., Ahr, H. J. et al. (2009). A review of the implementation of the embryonic stem cell test (EST). The report and recommendations of an ECVAM/ReProTect Workshop. Altern Lab Anim 37, 313-328.
155. Mattison, D. R. (2010). Environmental exposures and development. Curr Opin Pediatrics 22, 208-218. doi:10.1097/ MOP.0b013e32833779bf
156. McCollum, C. W., de Vancells, J. C., Hans, C. et al. (2016). Identification of vascular disruptor compounds by analysis in zebrafish embryos and mouse embryonic endothelial cells. Reprod Toxicol 70, 60-69. doi:10.1016/j.reprotox.2016.11.005
157. Miller, G. W. (2014). Improving reproducibility in toxicology. Toxicol Sci 139, 1-3. doi:10.1093/toxsci/kfu050
158. Moore, N., Bremer, S., Carmichael, N. et al. (2009). A modular approach to the extended one-generation reproduction toxicity study: Outcome of an ECETOC task force and International ECETOC/ECVAM workshop. Altern Lab Anim 37, 219-225.
159. Morgan, R. L., Thayer, K. A., Bero, L. et al. (2016). GRADE: Assessing the quality of evidence in environmental and occupational health. Environ Int 92-93, 611-616. doi:10.1016/j. envint.2016.01.004
160. OECD (2005). Guidance Document on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment. Series on Testing and Assessment No. 34, NV/JM/
161. MONO(2005)14. Paris: OECD Publishing. http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?doclanguag e=en&cote=env/jm/mono(2005)14
162. OECD (2007). Detailed Review Paper on Cell Transformation Assays for Detection of Chemical Carcinogens. Series on Testing and Assessment No. 31. Paris: OECD Publishing. http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO%282007%2918&docLanguage=En
163. OECD (2009). Carcinogenicity Studies. OECD Guidelines for Chemical Testing, TG No. 451. http://www.oecd.org/dataoecd/30/46/41753121.pdf
164. OECD (2011). OECD Guideline on Extended One-Generation Reproductive Toxicity Study. Series on Testing and Assessment No. 443. Paris: OECD Publishing. doi:10.1787/9789264122550-en
165. OECD (2015). Guidance Document on the in vitro Syrian Hamster Embryo (SHE) Cell Transformation Assay, Series on Testing and Assessment, No. 214. Paris: OECD Publishing. http://www.oecd.org/env/ehs/testing/Guidance-Document-on-the-invitro-Syrian-Hamster-Embryo-Cell-Transformation-Assay.pdf
166. OECD (2016). Guidance Document on the in vitro Bhas 42 Cell Transformation Assay. Series on Testing and Assessment, No. 231. Paris: OECD Publishing. https://www.oecd.org/env/ehs/testing/ENV_JM_MONO(2016)1.pdf
167. st century toxicology. Chem Res Toxicol 30, 43-52. doi:10.1021/ acs.chemrestox.6b00269
168. Pamies, D., Barreras, P., Block, K. et al. (2017a). A human brain microphysiological system derived from iPSC to study central nervous system toxicity and disease. ALTEX 34, 362-376. doi:10.14573/altex.1609122
169. Pamies, D., Bal-Price, A., Simeonov, A. et al. (2017b). Good cell culture practice for stem cells and stem-cell-derived models. ALTEX 34, 95-132. doi:10.14573/altex.1607121
170. Pamies, D., Block, K., Lau, P. et al. (2018a). Rotenone exerts developmental neurotoxicity in a human brain spheroid model. Toxicol Appl Pharmacol, Epub ahead of print. doi:10.1016/j. taap.2018.02.003
171. Pamies, D., Bal-Price, A., Chesne, C. et al. (2018b). Advanced good cell culture practice for human primary, stem cell-derived and organoid models as well as microphysiological systems. ALTEX, Epub ahead of print. doi:10.14573/altex.1710081.
172. Paparella, M., Daneshian, M., Hornek-Gausterer, R. et al. (2013). Uncertainty of testing methods – What do we (want to) know? ALTEX 30, 131-144. doi:10.14573/altex.2013.2.131
173. Paparella, M., Colacci, A. and Jacobs, M. N. (2016). Uncertainties of testing methods: What do we (want to) know about carcinogenicity? ALTEX 34, 235-252. doi:10.14573/altex.1608281
174. Paules, R. S., Aubrecht, J., Corvi, R. et al. (2011). Moving forward in human cancer risk assessment. Environ Health Persp 119, 739-743. doi:10.1289/ehp.1002735
175. Piersma, A. H., Genschow, E., Verhoef, A. et al. (2004). Validation of the postimplantation rat whole-embryo culture test in the international ECVAM validation study on three in vitro embryotoxicity tests. Altern Lab Anim 32, 275-307.
176. President’s Cancer Panel (2010). Reducing environmental cancer risk, NIH. https://deainfo.nci.nih.gov/advisory/pcp/annualreports/pcp08-09rpt/pcp_report_08-09_508.pdf
177. Pound, P. and Bracken, M. B. (2014). Is animal research sufficiently evidence based to be a cornerstone of biomedical research? BMJ 348, g3387. doi:10.1136/bmj.g3387
178. Pritchard, J. B., French, J. E., Davis, B. J. and Haseman, J. K. (2003). The role of transgenic mouse models in carcinogen identification. Environ Health Perspect 111, 444-454. doi:10.1289/ehp.5778
179. Rall, D. P. (2000). Laboratory animal tests and human cancer.
180. Drug Metab Rev 32, 119-128. doi:10.1081/DMR-100100565 Rodgers, K. M., Udesky, J. O., Rudel, R. A. and Brody, J. G. (2018). Environmental chemicals and breast cancer: An updated review of epidemiological literature informed by biological mechanisms. Environ Res 160, 152-182. doi:10.1016/j. envres.2017.08.045
181. Rovida, C., Longo, F. and Rabbit, R. R. (2011). How are reproductive toxicity and developmental toxicity addressed in REACH dossiers? ALTEX 28, 273-294. doi:10.14573/altex.2011.4.273
182. Rovida, C., Alépée, N., Api, A. M. et al. (2015). Integrated testing strategies (ITS) for safety assessment. ALTEX 32, 171-181. doi:10.14573/altex.1411011
183. Sanz, F., Pognan, F., Steger-Hartmann, T. et al. (2017). Legacy data sharing to improve drug safety assessment: The eTOX project. Nat Rev Drug Discov 16, 811-812. doi:10.1038/ nrd.2017.177
184. Sauer, J. M., Hartung, T., Leist, M. et al. (2015). Systems toxicology: The future of risk assessment. Int J Toxicol 34, 346-348. doi:10.1177/1091581815576551
185. Schaap, M. M., Wackers, P. F., Zwart, E. P. et al. (2015). A novel toxicogenomics-based approach to categorize (non-)genotoxic carcinogens. Arch Toxicol 89, 2413-2427. doi:10.1007/s00204-014-1368-6
186. Schmidt, C. W. (2002). Assessing assays. Environ Health Perspect 110, A248-251. doi:10.1289/ehp.110-a248
187. Schwarzman, M. R., Ackerman, J. R., Dairkee, S. H. et al. (2015). Screening for chemical contributions to breast cancer risk: A case study for chemical safety evaluation. Environ Health Perspect 123, 1255-1264. doi:10.1289/ehp.1408337
188. Seidle, T. (2006). Chemicals and cancer: What the regulators won’t tell you about carcinogenicity testing. PETA Europe Ltd. https://www.peta.de/mediadb/EUreport300.pdf
189. Selderslaghs, I. W. T., Blust, R. and Witters, H. E. (2012). Feasibility study of the zebrafish assay as an alternative method to screen for developmental toxicity and embryotoxicity using a training set of 27 compounds. Reprod Toxicol 33, 142-154. doi:10.1016/j.reprotox.2011.08.003
190. Silbergeld, E. K. (2004). Commentary: The role of toxicology in prevention and precaution. Int J Occup Med Environ Health 17, 91-102.
191. Sistare, F. D., Morton, D., Alden, C. et al. (2011). An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: Support for a proposal to modify current regulatory guidelines. Toxicol Pathol 9, 716-744. doi:10.1177/0192623311406935
192. Skardal, A., Shupe, T. and Atala, A. (2016). Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling. Drug Discov Today 21, 1399-1411. doi:10.1016/j. drudis.2016.07.003
193. Skardal, A., Murphy, S., Devarasetty, M. et al. (2017). Multitissue interactions in an integrated three-tissue organ-on-a-chip platform. Sci Rep 7, 8837. doi:10.1038/s41598-017-08879-x
194. Slikker, W. (2014). Of human-on-a-chip and humans: Considerations for creating and using microphysiological systems. Exp Biol Med 239, 1078-1079. doi:10.1177/1535370214537754
195. Smirnova, L., Harris, G., Leist, M. and Hartung, T. (2015). Cellular resilience. ALTEX 32, 247-260. doi:10.14573/altex.1509271
196. Smith, M. T., Guyton, K. Z., Gibbons, C. F. et al. (2016). Key characteristics of carcinogens as a basis for organizing data on mechanisms of carcinogenesis. Environ Health Perspect 124, 713-721. doi:10.1289/ehp.1509912
197. Spielmann, H., Genschow, E., Brown, N. A. et al. (2004). Validation of the rat limb bud micromass test in the international ECVAM validation study on three in vitro embryotoxicity tests. Altern Lab Anim 32, 245-274.
198. Spielmann, H., Seiler, A., Bremer, S. et al. (2006). The practical application of three validated in vitro embryotoxicity tests. The report and recommendations of an ECVAM/ZEBET workshop (ECVAM workshop 57). Altern Lab Anim 34, 527-538.
199. st century: Opportunities and challenges. ALTEX 30, 74-103. doi:10.14573/altex.2013.1.074 Stephens, M. L., Betts, K., Beck, N. B. et al. (2016).The emergence of systematic review in toxicology. Toxicol Sci 152, 10-16. doi:10.1093/toxsci/kfw059
200. Sturla, S. J., Boobis, A. R., FitzGerald, R. E. et al. (2014). Systems toxicology: From basic research to risk assessment. Chem Res Toxicol 27, 314-329. doi:10.1021/tx400410s
201. Sukardi, H., Chang, H. T., Chan, E. C. et al. (2011). Zebrafish for drug toxicity screening: Bridging the in vitro cell-based models and in vivo mammalian models. Expert Opin Drug Metab Toxicol 7, 579-589. doi:10.1517/17425255.2011.562197
202. Suter-Dick, L., Alves, P. M., Blaauboer, B. J. et al. (2015). Stem cell-derived systems in toxicology assessment. Stem Cells Develop 24, 1284-1296. doi:10.1089/scd.2014.0540
203. Takayama, S., Thorgeirsson, U. P. and Adamson, R. H. (2008). Chemical carcinogenesis studies in nonhuman primates. Proc Jpn Acad Ser B Phys Biol Sci 84, 176-188. doi:10.2183/ pjab.84.176
204. Tal, T., Kilty, C., Smith, A. et al. (2016). Screening for angiogenic inhibitors in zebrafish to evaluate a predictive model for developmental vascular toxicity. Reprod Toxicol 70, 70-81. doi:10.1016/j.reprotox.2016.12.004
205. Tennant, R. W., Stasiewicz, S., Mennear, J. et al. (1999). Genetically altered mouse models for identifying carcinogens. IARC Sci Publ 146, 123-150.
206. Thilly, W. G. (2003). Have environmental mutagens caused oncomutations in people? Nat Genet 34, 255-259. doi:10.1038/ ng1205
207. Tsaioun, K., Blaauboer, B. J. and Hartung, T. (2016). Evidence-based absorption, distribution, metabolism, excretion and toxicity (ADMET) and the role of alternative methods. ALTEX 33, 343-358. doi:10.14573/altex.1610101
208. Vaccari, M., Mascolo, M.G., Rotondo, F. et al. (2015). Identification of pathway-based toxicity in the BALB/c 3T3 cell model. Toxicol In Vitro 29, 1240-1253. doi:10.1016/j. tiv.2014.10.002
209. van der Laan, J. W., Kasper, P., Silva Lima, B. et al. (2016). Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties. Crit Rev Toxicol 46, 587-614. doi:10.3109/10408444.2016.1163664
210. Van Oosterhout, J. P., Van der Laan, J. W., De Waal, E. J. et al. (1997). The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. Regul Toxicol Pharmacol 25, 6-17. doi:10.1006/rtph.1996.1077
211. van Ravenzwaay, B. (2010). Initiatives to decrease redundancy in animal testing of pesticides. ALTEX 27, 159-161.
212. van Ravenzwaay, B., Dammann, M., Buesen, R. et al. (2011). The threshold of toxicological concern for prenatal developmental toxicity. Regulat Toxicol Pharmacol 59, 81-90. doi:10.1016/j. yrtph.2010.09.009
213. van Ravenzwaay, B., Dammann, M., Buesen, R. et al. (2012). The threshold of toxicological concern for prenatal developmental toxicity in rabbits and a comparison to TTC values in rats. Regul Toxicol Pharmacol 64, 1-8. doi:10.1016/j.yrtph.2012.06.004
214. van Ravenzwaay, B., Jiang, X., Luechtefeld, T. and Hartung, T. (2017). The threshold of toxicological concern for prenatal developmental toxicity in rats and rabbits. Regul Toxicol Pharmacol 88, 157-172. doi:10.1016/j.yrtph.2017.06.008
215. Voelkl, B., Vogt, L., Sena, E. S. and Würbel, H. (2018). Reproducibility of preclinical animal research improves with heterogeneity of study samples. PLoS Biology 16, e2003693. doi:10.1371/ journal.pbio.2003693
216. Wang, B. and Gray, G. (2015). Concordance of Noncarcinogenic Endpoints in Rodent Chemical Bioassays. Risk Analysis 35, 1154-1166. doi:10.1111/risa.12314
217. Waters, M. D. (2016). Introduction to predictive carcinogenicity. In Issues in Toxicology No. 28 Toxicogenomics in Predictive Carcinogenicity (Waters MD and Thomas RS, eds). Cambridge, UK: Royal Society of Chemistry. doi:10.1039/9781782624059-00001
218. Watson, D. E., Hunziker, R. and Wikswo, J. P. (2017). Fitting tissue chips and microphysiological systems into the grand scheme of medicine, biology, pharmacology, and toxicology. Exp Biol Med 242, 1559-1572. doi:10.1177/1535370217732765
219. Weigt, S., Huebler, N., Braunbeck, T. et al. (2010). Zebrafish teratogenicity test with metabolic activation (mDarT): Effects of phase I activation of acetaminophen on zebrafish Danio rerio embryos. Toxicology 275, 36-49. doi:10.1016/j. tox.2010.05.012
220. Worth, A., Barroso, J. F., Bremer, S. et al. (2014). Alternative Methods for Regulatory Toxicology – A State-of-the-art Review, 470pp. JRC Report 26797. https://bit.ly/2q91DiM